Identifying Biomarkers for Early Detection of Pancreatic Cancer
A clinical trial for at-risk people is looking for biomarkers that can indicate pancreatic cancer is growing.
AACR Annual Meeting 2021 Highlights
Let's Win and the Lustgarten Foundation bring you the pancreatic cancer research highlights of the 2021 AACR Annual Meeting,
New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
Artificial Intelligence and Early Detection of Pancreatic Cancer
How can AI be used in the early detection of pancreatic cancer? Dr. Michael Rosenthal reviews the current state of the field.
Searching for Potential Pancreatic Cancer Blood Biomarkers
Researchers are using blood samples to follow people considered at-risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Pancreatic Cancer Patients in the UK Benefit From Unique Precision Medicine Project
Dr. David Chang explains the Precision Panc initiative, a program through the UK's NHS that helps pancreatic cancer patients find treatments.
Genetic Testing Can Help Those You Love
Dr. Fay Kastrinos, director of the Muzzi Mirza Pancreatic Cancer Prevention and Genetics Program at Columbia University Medical Center, explains the value of genetic testing for cancer prevention and treatment.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
A Registry for Those at Risk for Pancreatic Cancer
If you’ve lost relatives to pancreatic cancer or have a genetic mutation tied to the disease, joining a tumor registry can help doctors identify early detection and screening options.
A Newly Identified Biomarker Panel Shows Promise in Earlier Pancreatic Cancer Detection
The first pancreatic cancer blood test may soon be a reality, as a biomarker panel from the lab of Dr. Ken Zaret shows promise in early testing.